Novel three-step pretargeted radioimmunotherapy offers safe, effective treatment
Researchers at Memorial Sloan Kettering Cancer Center in New York City and Massachusetts Institute of Technology in Boston have developed a new, three-step system that uses nuclear medicine to target and eliminate colorectal cancer. In this study with a mouse model, researchers achieved a 100-percent cure rate—without any treatment-related toxic effects. The study is reported in the November featured article in The Journal of Nuclear Medicine.
Until now, radioimmunotherapy (targeted therapy) of solid tumors using antibody-targeted radionuclides has had limited therapeutic success. “This research is novel because of the benchmarks reached by the treatment regimen, in terms of curative tumor doses, with non-toxic secondary radiation to the body’s normal tissues,” explains Steven M. Larson, MD, and Sarah Cheal, PhD, of Memorial Sloan Kettering Cancer Center. “The success in murine tumor models comes from the unique quality of the reagents developed by our group, and the reduction to practice methodology, including a theranostic approach that can be readily transferred, we believe, to patients.”
Theranostics, a term derived from therapy and diagnostics, is the use of a single agent to both diagnose and treat disease. The theranostic agent first finds the cancer cells, then destroys them, leaving healthy cells unharmed—minimizing side effects and improving quality of life for patients.
In this study, the glycoprotein A33 (GPA33), an antigen found on over 95 percent of primary and metastatic human colorectal cancers, was targeted with a bispecific antibody for A33 tumor antigen and a second antibody for a small-molecule radioactive hapten, a complex of lutetium-177 (177Lu) and S-2-(4-aminobenzyl)1,4,7,10-tetraazacyclododecane tetra-acetic acid (177Lu-DOTA-Bn).
The DOTA-pretargeted radioimmunotherapy (PRIT) strategy was tested on a mouse model. In randomly selected mice undergoing treatment, serial SPECT/CT imaging was used to monitor treatment response and calculate radiation-absorbed doses to tumors. All the DOTA-PRIT–treated animals tolerated the treatment well, and all 9 assessed mice had no trace of cancer remaining upon microscopic examination. There was also no detectable radiation damage to critical organs, including bone marrow and kidneys.
The 100-percent cure rate in the mouse model is a promising preliminary finding that suggests that anti-GPA33-DOTA-PRIT will be a potent radioimmunotherapy regimen for GPA33-positive colorectal cancer tumors in humans.
According to the Centers for Disease Control and Prevention, colorectal cancer is the third most common cancer affecting both men and women. Each year, approximately 140,000 new cases are diagnosed in the United States and 50,000 people die of the disease.
The applications of this nuclear medicine treatment protocol could extend to other cancers as well. Larson and Cheal state, “If clinically successful, our approach will expand the repertoire of effective treatments for oncologic patients. The system is designed as a ‘plug and play’ system, which allows for the use of many fine antibodies targeting human tumor antigens and is applicable, in principle, to virtually all solid and liquid tumors in man.” They add, “There is a huge unmet need in oncology, especially for the solid tumors, for curative treatments for advanced disease. This includes, colon, breast, pancreas, melanoma, lung, and esophageal, to name a few.”
The Latest on: Colorectal cancer
- There’s an alarming increase in pancreas and colorectal cancer cases, globallyon October 22, 2019 at 8:32 pm
Global death rates for pancreatic cancer and incidence rates for colorectal cancer both increased by 10 per cent between 1990 and 2017, the results of a major study conducted across 195 countries ...
- Trovagene Announces Positive Response to Treatment in Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Canceron October 22, 2019 at 5:10 pm
Highly aggressive KRAS-mutated tumors account for ~50% of metastatic colorectal cancer (mCRC); no targeted treatments available and response to standard-of-care is only 5% -- Decreases in tumor KRAS ...
- Researchers use EHRs to identify cancer symptom clusterson October 22, 2019 at 11:53 am
Patients with chronic diseases such as breast cancer or colorectal cancer often experience fatigue, pain, depression and other symptoms which can lead to distress and functional impairment if left ...
- A 16q22.1 variant confers susceptibility to colorectal cancer as a distal regulator of ZFP90on October 22, 2019 at 5:24 am
Genome-wide association studies (GWASs) implicate 16q22.1 locus in risk for colorectal cancer (CRC). However, the underlying oncogenic mechanisms remain unknown. Here, through comprehensive filtration ...
- Colorectal and pancreatic cancer rates up 10% in last 30 years, major study revealson October 22, 2019 at 5:05 am
The results of a major study across 195 countries, presented today at UEG Week Barcelona 2019, indicate that global death rates for pancreatic cancer and incidence rates for colorectal cancer both ...
- Application of RNA-sequencing to identify transcriptome modification by DCLK1 in colorectal cancer cellson October 21, 2019 at 3:27 am
All prices are NET prices. VAT will be added later in the checkout. De Dosso S, Sessa C, Saletti P. Adjuvant therapy for colon cancer: present and perspectives. Cancer Treat Rev. 2009;35:160–6.
- Early Signs Of Colon Cancer That Warn You Of Conditionon October 17, 2019 at 6:08 pm
About 60 percent of colorectal cancer deaths can be prevented by early screening, according to statistics put out by the nonprofit organization Fight Colorectal Cancer (Fight CRC). At an early stage, ...
- More Evidence for ctDNA's Potential Role in Colon Canceron October 17, 2019 at 2:05 pm
Circulating tumor DNA (ctDNA) in post-chemotherapy blood samples identified patients with stage III colorectal cancer at high risk of disease recurrence, a prospective study from Australia found. In ...
- Colorectal Cancer Therapeutics Market 2019-2026 | Focuses on the Global Key Manufacturers, Competition Landscape and SWOT Analysison October 16, 2019 at 9:03 am
Oct 16, 2019 (Market Prediction via COMTEX) -- In 2018, the Colorectal Cancer Therapeutics Market revenue was around US$ XX Mn and the Market share was XX%, and it will be projected to reach US$ XX Mn ...
- Screen for colorectal cancer at age 45, American Cancer Society recommendson October 16, 2019 at 6:00 am
In the sprig of 2018, the American cancer Society changed its recommendations about colorectal cancer screening in response to more fatal cases in people under 50. They now recommend that average-risk ...
via Google News and Bing News